Pediatric GLP-1 Nutritional Deficiency Study
Analysis based on 9 articles · First reported Sep 21, 2026 · Last updated Sep 24, 2026
The study could pressure GLP-1 manufacturers Novo Nordisk and Eli Lilly and Company by highlighting safety concerns and potential regulatory scrutiny over pediatric prescribing, though the observational nature limits immediate market disruption. It may also boost demand for nutritional supplements and counseling services, benefiting companies like FrieslandCampina — FrieslandCampina WAMCO and Roquette Frères that supply complementary nutrition solutions.
A study published in the journal Childhood Obesity found that nearly one in six children and teenagers (16.8%) prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes were diagnosed with a nutritional deficiency within their first year of treatment. The research, led by senior author Justin Ryder of Lurie Children s Hospital and Northwestern University, analyzed national administrative claims data from 2017 to 2022 covering over 100 million patients, identifying 2,031 GLP-1 users aged 10 to 17. Vitamin D deficiency was the most common diagnosis at 12.4%, followed by nutritional anemia at 1.55% and iron-deficiency anemia at 1.44%. The most prescribed GLP-1s in the sample were liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%). Researchers found that only about 5% of patients received nutritional counseling within 30 days of starting treatment and less than 25% within six months. The study is observational and shows association rather than causation. The American Academy of Pediatrics began recommending GLP-1 therapy for childhood obesity in 2023, emphasizing nutritional support. The findings add to growing research on GLP-1 risks and could influence prescribing practices and monitoring guidelines for pediatric patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard